Cellectis S.A. (CLLS) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
CLLS currently has 72.1M outstanding shares. with significant dilution risk as 272M authorized shares could dilute existing holders by 377.0%. The company has minimally diluted shareholders by 0.48% over the past 2 years.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| Jul 02, 2025 |
F-3 filing: Cellectis S.A. intends to offer ordinary shares (including in the form of ADSs), preferred shares, and warrants for an aggregate offering price of up to $200,000,000. |
72M | 270M |
| Mar 14, 2025 |
20-F filing | 72.1M shares outstanding |
72M | 140M |
| Jan 15, 2025 |
F-3 filing: This F-3 filing relates to the potential resale of up to 44,000,000 ordinary shares (including ADSs) of Cellectis S.A. by AstraZeneca Holdings B.V., the selling shareholder. |
72M | 140M |
| Apr 29, 2024 |
20-F filing | 71.8M shares outstanding |
72M | 99M |
| Mar 14, 2023 |
20-F filing | 45.7M shares outstanding |
46M | 130M |
| Jun 24, 2022 |
F-3 filing: Cellectis S.A. is filing an F-3 registration statement to offer up to $200,000,000 of Ordinary Shares, American Depositary Shares, representing Ordinary Shares, and Preferred Shares from time to time. |
45M | 130M |
| Mar 03, 2022 |
20-F filing | 45.5M shares outstanding |
45M | 0 |
| Mar 04, 2021 |
20-F filing | 42.8M shares outstanding |
43M | 0 |
| Mar 05, 2020 |
20-F filing | 42.5M shares outstanding |
42M | 0 |